AR122778A1 - Derivados de tetrazol como inhibidores de trpa1 - Google Patents
Derivados de tetrazol como inhibidores de trpa1Info
- Publication number
- AR122778A1 AR122778A1 ARP210101794A ARP210101794A AR122778A1 AR 122778 A1 AR122778 A1 AR 122778A1 AR P210101794 A ARP210101794 A AR P210101794A AR P210101794 A ARP210101794 A AR P210101794A AR 122778 A1 AR122778 A1 AR 122778A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- fluoroalkyl
- alkyl
- trpa1
- tetrazole derivatives
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003536 tetrazoles Chemical class 0.000 title abstract 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 title 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- 102100031366 Ankyrin-1 Human genes 0.000 abstract 1
- 101710191059 Ankyrin-1 Proteins 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Derivados de tetrazol que son inhibidores de potencial de receptor transitorio anquirina 1 (TRPA1) y que son útiles para el tratamiento de las enfermedades que se pueden tratar mediante inhibición de TRPA1. Asimismo, composiciones farmacéuticas que lo contienen, y procesos para la preparación de dichos compuestos. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) en donde A se selecciona del grupo que consiste en fenilo, tiofenilo, benzotiofenilo o benzofuranilo, sustituidos o no sustituidos con uno, dos o tres miembros del grupo R³ que consiste en halógeno, CN, C₁₋₄-alquilo, O-C₁₋₄-alquilo, C₁₋₄-fluoroalquilo, O-C₁₋₄-fluoroalquilo, C₃₋₄-cicloalquilo, O-C₃₋₄-cicloalquilo, C₃₋₄-ciclofluoroalquilo y O-C₃₋₄-ciclofluoroalquilo, o A se selecciona del grupo que consiste en los compuestos del grupo de fórmulas (2); E se selecciona del grupo que consiste en O, S, SO, SO₂ y CH₂; y R¹ y R² se seleccionan independientemente del grupo que consiste en H, C₁₋₄-alquilo, C₁₋₄-fluoroalquilo y halógeno, o R¹ y R², junto con el átomo de carbono al que están unidos, forman un anillo de ciclopropilo o ciclobutilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20182987 | 2020-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122778A1 true AR122778A1 (es) | 2022-10-05 |
Family
ID=71401655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101794A AR122778A1 (es) | 2020-06-29 | 2021-06-28 | Derivados de tetrazol como inhibidores de trpa1 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11891403B2 (es) |
| JP (1) | JP7539500B2 (es) |
| KR (1) | KR20230028546A (es) |
| CN (1) | CN116157130A (es) |
| AR (1) | AR122778A1 (es) |
| AU (1) | AU2021301140A1 (es) |
| BR (1) | BR112022021386A2 (es) |
| CA (1) | CA3182143A1 (es) |
| CL (1) | CL2022003325A1 (es) |
| CO (1) | CO2022016762A2 (es) |
| CR (1) | CR20220668A (es) |
| DO (1) | DOP2022000270A (es) |
| EC (1) | ECSP22088958A (es) |
| IL (1) | IL299172A (es) |
| MX (1) | MX2022016272A (es) |
| PE (1) | PE20240594A1 (es) |
| SA (1) | SA522441973B1 (es) |
| TW (1) | TW202216729A (es) |
| WO (1) | WO2022002780A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023015219A2 (pt) | 2021-04-14 | 2023-11-07 | Boehringer Ingelheim Int | Derivados de 3h,4h,5h,6h,7h-pirimido [4,5-b][1,4]oxazina-4,6-diona como inibidores de trpa1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| EP3544979B1 (en) | 2016-11-28 | 2021-08-04 | F. Hoffmann-La Roche AG | Oxadiazolones as transient receptor potential channel inhibitors |
| BR112023015219A2 (pt) | 2021-04-14 | 2023-11-07 | Boehringer Ingelheim Int | Derivados de 3h,4h,5h,6h,7h-pirimido [4,5-b][1,4]oxazina-4,6-diona como inibidores de trpa1 |
-
2021
- 2021-06-24 US US17/356,782 patent/US11891403B2/en active Active
- 2021-06-25 CN CN202180045923.7A patent/CN116157130A/zh active Pending
- 2021-06-25 MX MX2022016272A patent/MX2022016272A/es unknown
- 2021-06-25 CA CA3182143A patent/CA3182143A1/en active Pending
- 2021-06-25 WO PCT/EP2021/067467 patent/WO2022002780A1/en active Application Filing
- 2021-06-25 PE PE2022003064A patent/PE20240594A1/es unknown
- 2021-06-25 KR KR1020237003323A patent/KR20230028546A/ko unknown
- 2021-06-25 CR CR20220668A patent/CR20220668A/es unknown
- 2021-06-25 AU AU2021301140A patent/AU2021301140A1/en active Pending
- 2021-06-25 IL IL299172A patent/IL299172A/en unknown
- 2021-06-25 JP JP2022578725A patent/JP7539500B2/ja active Active
- 2021-06-25 BR BR112022021386A patent/BR112022021386A2/pt unknown
- 2021-06-28 AR ARP210101794A patent/AR122778A1/es unknown
- 2021-06-28 TW TW110123498A patent/TW202216729A/zh unknown
-
2022
- 2022-11-21 EC ECSENADI202288958A patent/ECSP22088958A/es unknown
- 2022-11-22 CO CONC2022/0016762A patent/CO2022016762A2/es unknown
- 2022-11-25 CL CL2022003325A patent/CL2022003325A1/es unknown
- 2022-11-30 DO DO2022000270A patent/DOP2022000270A/es unknown
- 2022-12-29 SA SA522441973A patent/SA522441973B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022003325A1 (es) | 2023-03-31 |
| WO2022002780A1 (en) | 2022-01-06 |
| TW202216729A (zh) | 2022-05-01 |
| CR20220668A (es) | 2023-03-10 |
| JP7539500B2 (ja) | 2024-08-23 |
| DOP2022000270A (es) | 2023-01-15 |
| CA3182143A1 (en) | 2022-01-06 |
| SA522441973B1 (ar) | 2024-07-21 |
| KR20230028546A (ko) | 2023-02-28 |
| ECSP22088958A (es) | 2022-12-30 |
| US11891403B2 (en) | 2024-02-06 |
| US20210403482A1 (en) | 2021-12-30 |
| MX2022016272A (es) | 2023-02-09 |
| CO2022016762A2 (es) | 2022-12-09 |
| CN116157130A (zh) | 2023-05-23 |
| IL299172A (en) | 2023-02-01 |
| PE20240594A1 (es) | 2024-03-21 |
| EP4171571A1 (en) | 2023-05-03 |
| JP2023533189A (ja) | 2023-08-02 |
| BR112022021386A2 (pt) | 2023-01-10 |
| AU2021301140A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR109349A1 (es) | Compuestos y usos | |
| UY37795A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20190705A1 (es) | COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING | |
| AR096339A1 (es) | Agonistas del receptor de somatostatina subtipo 4 (sstr4) | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR104307A1 (es) | Tetralinas de ácido 3-espirocíclico-6-hidroxámico como inhibidores de hdac | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR048537A1 (es) | Derivados de nucleosidos para tratar infecciones por virus de hepatitis c. | |
| AR063878A1 (es) | Compuestos de pirrol-piridina y composicion farmaceutica | |
| AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR110790A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR061663A1 (es) | Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados. | |
| BR112016019462B8 (pt) | Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase | |
| AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
| AR061583A1 (es) | Acidos 6-(bencilo sustituido con heterociclil)-4-oxiquinolin carboxilicos, inhibidores de vih-integrasas, composiciones farmaceuticas que los contienen y usos como agentes anti-vih. | |
| AR113878A1 (es) | Compuestos de biarilo sustituido como inhibidores de indolamina 2,3-dioxigenasa (ido) | |
| BR112022001922A2 (pt) | Compostos de heteroarila de anel fundido como inibidores de ripk1 | |
| AR122778A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| AR122779A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| AR126048A1 (es) | Derivados heterocíclicos condensados |